The Size of the Stem Cell Market in the Asia Pacific is valued at USD 3310 million in 2019 and estimated to reach USD 5330 million by the end of 2024 with a CAGR of 10%, during the forecast period 2019-2024.
Market Overview:
The allogeneic stem cell therapy is expected to command the largest share of the market in 2018. The market is expected to grow rapidly because of the extensive research and development which is being done. In the field of life sciences, one of the most promising markets at the moment is the global stem cell market and is expected to grow exponentially in the coming years as stem cells allow cost-effective treatment of many illnesses that currently have no or ineffective treatment.
Market Drivers:
Regenerative medicine is perhaps the most important use of stem cells, and other important areas include oncology, hematology, orthopedics, cardiology, and neurology. Another widely found application is drug discovery and development. Stem cells are kind of a research tool, as their in vitro study would allow scientists to understand in depth about the role of various organs and the development of particular illnesses; stem cells may also possibly allow drug developers to test emerging therapies on diseased cells. Stem cell therapy has shown substantial potential to treat cancer successfully. Cancer stem cells that have been tested on animals have shown satisfactory results.
Some of the key drivers of the Asia-Pacific stem cell market are improved funding from various organizations for research and development for unmet medical needs, growing industry attention on stem cell research, and growing awareness across the world about stem cell therapies. Factors such as improving economic stability, better income, growing medical tourism in emerging countries such as India and China, patients from the U.S. and Europe opting for affordable yet quality treatment in these countries, thriving contract research industry, and high rate of chronic diseases is currently driving the stem cells market in Asia-Pacific region. While on the other hand, ethical issues are involved in stem cell research and strict regulations to conduct trials on humans are some of the restraining factors. Also, factors such as lack of required infrastructure and complications associated with the preservation of stem cells are limiting the growth of the stem cells market.
This research report segmented and sub-segmented the Asia Pacific Stem Cell Market into the following categories:
By Treatment mode: allogeneic and autologous stem cell therapy.
On the Basis of Treatment Mode, the allogeneic stem cell therapy is expected to command the largest share of the market in 2018.
By Cells Type: adult stem cells, induced pluripotent stem cells, human embryonic stem cells, and others.
On the Basis of Cells Type, the adult stem cells hold the highest share, while the market share of induced pluripotent stem cells is likely to grow in the next few years.
By Technology: cell acquisition, cell production, cryopreservation, and other sub-segments.
By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC.
On the Basis of the Region, the Asia-Pacific stem cell market is expected to grow the fastest in this forecast period, mainly because of better regulatory support through encouraging government policies and increasing awareness among the public.
Some of the Promising Companies Operating the Asia Pacific Stem Cell Market Profiled in the Report are Athersys, StemCells Inc, Cryo-Cell International, Geron Corporation, Mesoblast Ltd, Aastrom Biosciences Inc, Celgene Corporation, Invitrogen, Cytori Therapeutics Inc
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By mode of treatment
5.1.1 Autologous
5.1.2 Allogeneic
5.2 By application
5.2.1 CNS
5.2.2 CVS
5.2.3 GIT
5.2.4 Regenerative Medicine
5.2.5 Musculoskeletal
5.2.6 Eye & Immune System Development
5.2.7 Blood Disorders
5.3 By technology
5.3.1 Cell Acquisition
5.3.2 Cell Production
5.3.3 Cryopreservation
5.3.4 Expansion
5.3.5 Sub-Culture
5.4 By type
5.4.1 Adult Stem Cells
5.4.2 Human Embryonic Cells
5.4.3 Pluripotent Stem Cell
5.4.4 Natural Rosette Cells
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Athersys
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 StemCells
8.3 Cryo Cell International
8.4 Geron Corporation
8.5 Mesoblast
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.8 Invitrogen
8.9 Cytori Therapeutics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
